Non-small cell lung cancer (NSCLC) continues be one of the most frequent oncological diseases both in incidence and mortality. Over the past ten years, due to the targeted and immunotherapy, significant success has been achieved in the treatment of metastatic forms NSCLC, but until recently, approaches to the treatment of earlier stages of NSCLC have remained unchanged. So, the standard treatment of locally-advanced unresectable NSCLC remained chemo-radiation (concurrent or sequential). The first study that has demonstrated the possibility of improving treatment results (including long term results) using an innovative approach from combination of durvalumab immunotherapy with chemo-radiation therapy (CRT) as an integrated treatment complex in this category of patients, has become the PACIFIC study. In Russia, durvalum ab was registered in July 2019 for using in patients with locally advanced NSCLC who have not progressed after CRT, so the experience of its administration in real clinical practice is still small. In this article, we summarized our local experience with durvalumab treatment in seven patients and presented more detailed one of the clinical cases. A patient with stage III unresectable NSCLC began receiving durvalumab therapy in October 2018, 2 months after completing a course of sequential CRT. Currently, after 12 months of therapy, the stabilization of the disease persists, the patient continues treatment.

Erdheim-Chester disease (ECD) is a rare systemic disease with an unknown etiology, which is characterized by infiltration of the organs CD68⁺, CD1a by non-langerhans cell histiocytes and occupies an intermediate position between malignant and immune disorders. The medical literature describes a little more than 750 sick peoplearound the world, and the 17 with a lesion of the bronchial tree. The largest study on this pathology includes only 53 patients. The article presents a case of personal experience of successful treatment of a patient with a morphologically established diagnosis of ECD, which differs from the standard options both in the clinical picture and in the approach to treatment. The purpose of the publication is differential diagnosis between malignant neoplasms of the skin or bronchi and ECD.

Vascular abnormalities are a hallmark of most solid tumors including NSCLC and facilitate immune evasion. Nintedanib is oral multitarget angiokinase inhibitor, and in combination with docetaxel is an important and effective second-line treatment option for locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology with the maximum benefit in patients who progressed within 9 months after start of first-line treatment or with progressive disease as best response to first-line chemotherapy. However, immunotherapy is now playing the main role. Recent studies showed the potential clinical benefit of nintedanib plus docetaxel in patients who failed prior immune checkpoint inhibitor. Besides nintedanib with docetaxel should be the preferred choice of a second-line treatment after platinum-based doublet chemotherapy in case of early progression, low level or negative expression of PD-L1, concomitant use of steroids.

The percentage of older adults with colorectal cancer has been increased. It is a worldwide trend. We proved a necessity of using special predictive scales Charlson, CR-POSSUM, ACPGBI and use of Comprehensive geriatric assessment (CGA) as a part of preoperation eximination among older adults. This approach is improved outcomes of surgical treatment and increased the number of patients undergoing radical cancer therapy.

Purpose. To determine the diagnostic value of threephase scintigraphy in the evaluation of the preoperative chemotherapy of soft tissue sarcomas of the extremities on different diagnostic stages. Material and methods. We analyzed the data of 76 patients with extremity soft tissue sarcomas. The study included data from 28 patients who underwent three-phase scintigraphy with Technetril ^99mTc. Scintigraphic data before and after neoadjuvation chemotherapy were analyzed in 16 patients, before and during chemotherapy — in 6 patients, only during chemotherapy — in 1 and only after all courses of chemotherapy — in 5 patients. Results. The sensitivity of the method (prediction of grade III–IV pathologic response) was 100 %, specificity (prediction of grade I–II pathologic response) was 87%. The predictive value of positive and negative results was 63 and 100%, respectively. Conclusion. A three-phase scintigraphy with Technetril ^99mTc is a highly informative method for evaluating the effectiveness of preoperative chemotherapy in patients with sarcomas of soft tissues of the extremities.

This article provides an overview of current nutritional support recommendations for autologous hematopoietic stem cell transplantation recipients, and the impact of nutritional status on infectious complications frequency.

Results are presented of own studies of extracellular DNA (exDNA) in experiment of animals with transplanted ovarian cancer, after exposure to ionizing radiation, with benign prostatic hyperplasia, clinical studies in patients with chronic obstructive pulmonary disease and with acute disorders of cerebral circulation. The possibilities of exDNA determination for minimally invasive diagnostics in oncological diseases, formation of risk groups, monitoring of diseases, studying mechanisms of action and individual sensitivity to drug therapy are considered.

This is a description of a case of extremely rare pathology, a primary mucinous adenocarcinoma of renal pelvis. The survey data, including CT-scan, as well as the results of histological, immunohistochemical and molecular genetic studies are presented. The disease progressed after surgical treatment; chemotherapy regimens and their effectiveness are given.

Regorafenib is an agent of targeted cancer therapy, that is a multikinase inhibitor of angiogenesis, oncogenesis, microenvironment and tumor immune system. Due to the unique mechanism of action, regorafenib is highly effective in the treatment of various tumors. The most common adverse event associated with regorafenib, leading to a dose reduction or its cancellation, is a manifestation of skin toxicity — hand-foot skin reaction. The review compiles published data based on research and experience in managing this dermatological adverse event. Adequate staff and patient awareness, monitoring, prevention, and treatment are necessary to reduce the incidence, duration, and severity of hand-foot skin reaction associated with regorafenib. Determining the optimal management for patients with this complication becomes an essential component of the complex treatment of patients receiving regorafenib anti-tumor therapy, especially considering the fact that hand-foot skin reaction is a marker of its effectiveness.